NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS CONTINUED As required by IFRS 3, the fair value adjustment to inventory for finished goods represents the selling price of the goods less costs to dispose and a reasonable profit allowance for the selling effort.
Work in progress has been similarly valued and includes an allowance for the costs to complete.
The resulting fair value adjustment of 4,686,000 has been recognised.
The acquisition of ACMI has provided Gyrus with the opportunity to combine ACMIs urology, gynaecology and endoscopic expertise with Gyruss tissue management technology in these fields.
This enables the enlarged Group to meet two key requirements of surgeons the ability to visualise the operative site and the ability effectively to manipulate tissue with minimum collateral damage.
Goodwill of 180 million has arisen as a result of the synergistic and integration benefits of combining the two organisations.
Since the date of acquisition, ACMI has contributed the following to the operating profit of the Group: 000 Revenue 50,431 Cost of sales 23,805 Gross profit 26,626 Selling and distribution expenses Selling and distribution 12,507 Amortisation of intangible assets 2,524 Research and development expenses Research and development 2,473 Amortisation of intangible assets 1,349 General and administrative expenses 3,057 Operating profit 4,716 Had the acquisition taken place on 1 January 2005, ACMI would have contributed the following to the operating profit of the Group: 000 Revenue 111,920 Cost of sales 49,570 Gross profit 62,350 Selling and distribution expenses Selling and distribution 27,805 Amortisation of intangible assets 5,706 Research and development expenses Research and development 6,277 Amortisation of intangible assets 3,050 General and administrative expenses 8,511 Operating profit 11,001 Amortisation of intangible assets as if acquisition had occurred on 1 January 2005.
Restructuring As a result of the acquisition of American Cystoscope Makers Inc, a number of restructuring costs have been incurred across the Group.
The total charge for the year ending 31 December 2005 amounted to 2,369,000 2004: nil.
An analysis of these costs is shown below.
2005 000 Severance costs 1,320 Short term sales commission alignment 352 Demonstration equipment write-off 148 Alignment of global enterprise resource planning systems 456 Other costs 93 2,369 4.
Other operating income 2005 2004 000 000 Income from research and development costs recharged to third party 1,501 641 Gyrus Group PLC Annual Report and Accounts 2005 58
